A Phase 1/2 interventional study of Hypidone Hydrochloride tablets in Major Depressive Disorder, sponsored by Zhejiang Huahai Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-10-30.
Sponsored by Zhejiang Huahai Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Depressive Disorder, Major with a site in China — 74 open to participants now, 77 under way, 5 of them phase 3. Depressive Disorder, Major · China.
Among the 206 studies in Depressive Disorder, Major with a site in China, this one is the 147th largest by enrollment of the 173 interventional ones that give a count, is one of 10 that started in 2018, is one of 2 in phase 1/2, and was the 46th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →74 of the 206 studies in Depressive Disorder, Major with a site in China are open now. Recruiting first, the newest first:
Qilu Hospital of Shandong University · Sites in China
Ages 11–19
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
Eli Lilly and Company · Sites in China, United States, Australia and 12 more countries
Ages 18–75
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
Guo Wenbin · Sites in China
Ages 18–45
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 24 · Phase 3 20 · Phase 4 19
First in 2004; this study’s year is marked. 10 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 120 across the 173 interventional studies, 240 across the 33 observational. Of the 76 that completed or were terminated, 8 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 206 have an industry lead sponsor. The 10 most frequent:
Zhejiang Huahai Pharmaceutical Co., Ltd. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Zhejiang Huahai Pharmaceutical Co., Ltd. has 4 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
21 of the studies in Depressive Disorder, Major with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04984512Phase 3Sunshine Lake Pharma Co., Ltd.The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder | 2027-07 |
| NCT07282366Jian-Jun OuVideo Intervention to Reduce Depression-related Stigma Among Adolescents | 2026-11-20 |
| NCT06913309Peking University Sixth HospitalClinical Efficacy, Safety, and Applicability of Home-based Bright Light Therapy in Outpatient Adolescents With Major Depressive Disorder | 2026-11-30 |
| NCT06409325Shanghai Mental Health CenterEffectiveness of MST Versus ECT for Major Depressive Episode | 2026-12-30 |
| NCT07873060Qilu Hospital of Shandong UniversityComparing 10 Hz rTMS and iTBS for Adolescent Depression | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 206 studies in Depressive Disorder, Major with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the safety and efficacy of Hypidone Hydrochloride tablets in treatment of patients with major depressive disorder (MDD) by evaluating the change of MADRS total score from baseline to week 6.
A total of 40 major depressive disorder (MDD) subjects between the ages of 18-65 who have current major depressive disorder diagnosed by DSM-5 will be recruited, Subjects will be accepted into the protocol after an opportunity to review and provide voluntary written informed consent and completion of a comprehensive medical and psychiatric history, physical examination, mental status examination, and routine laboratory assessments The subjects will accept the drug treatment twice daily orally for 6 weeks, During the treatment follow up will occur at 8±1 days after treatment, 15±1 days after treatment, 29±2 days after treatment ,43±2 days after treatment to evaluate the safety and efficacy of the drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg of Hypidone Hydrochloride tablets
Drug: Hypidone Hydrochloride tablets
20 mg of Hypidone Hydrochloride tablets
Drug: Hypidone Hydrochloride tablets
Hypidone Hydrochloride tablets 10 or 20mg/day Study drug is to be given orally, twice daily, for 6 weeks
Change in Montgomery-Asberg Depression Rating Scale (MADRS)
Change from baseline in MADRS scores,the \*total\* score ranges\[0,60\],higher values represent a worse outcome
Time frame: Screening,Baseline,8 day after treatment,15 day after treatment,29 day after treatment,43 day after treatment
Change in Hamilton Depression Scale 17 items(HAMD17)
Change from baseline in HAMD17 scores,the \*total\* score ranges\[0,50\],higher values represent a worse outcome
Time frame: Baseline,8 day after treatment,15 day after treatment,29 day after treatment,43 day after treatment
Change in Hamilton Anxiety Rating Scale (HAM-A)
Change from baseline in HAM-A scores,the \*total\* score ranges\[0,56\],higher values represent a worse outcome
Time frame: Baseline, 8 day after treatment,15 day after treatment,29 day after treatment ,43 day after treatment
Change in Clinical Global Impression of Severity Scale(CGI-S)
Change from baseline in CGI-S scores,the \*total\* score ranges\[0,7\],higher values represent a worse outcome
Time frame: Screening,Baseline, 8 day after treatment,15 day after treatment,29 day after treatment,43 day after treatment
Change in Clinical Global Impression of Improvement Scale(CGI-I)
the \*total\* score ranges\[0,7\],higher values represent a worse outcome
Time frame: 8 day after treatment,15 day after treatment,29 day after treatment,43 day after treatment
Columbia-Suicide Severity Rating Scale (C-SSRS)
Safety index,no total score
Time frame: Baseline,15 day after treatment,43 day after treatment
Ran from Feb 2018 to primary completion in Jul 2018, 4 months.
Of 31 phase 1/2 interventional studies under Depressive Disorder, Major, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 75. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhejiang Huahai Pharmaceutical Co., Ltd.